Results 181 to 190 of about 140,144 (311)

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy. [PDF]

J Adv Pract Oncol
Guerrero MD.
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system. [PDF]

Ther Adv Psychopharmacol
Kang N, Jang JS, Joo SW, Lee JH, Jeong JH, Kim M, Ahn YM, Kwon JS, Kim YS, Lee JS, Kim SH.   +10 more
europepmc   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

Allergy, EarlyView.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler, Sally E. Wenzel, Steve D. Groshong, Mario Castro, Ian D. Pavord, Klaus F. Rabe, Elizabeth Laws, Alexandre Jagerschmidt, Kaitlyn Gayvert, Sivan Harel, Jennifer D. Hamilton, Nikhil Amin, Lu Zhang, Heming Xing, Anissa Elfakir, Bema Coulibaly, Souâd Naimi, Sara Hamon, Paul J. Rowe, Frank Nestle, Danen M. Cunoosamy, Emanuele de Rinaldis, Leda P. Mannent   +22 more
wiley   +1 more source

Isolated Neutropenia as a Sentinel of High-Risk Clonal Evolution: Acute Myeloid Leukemia With Myelodysplasia-Related Changes Harboring <i>TP53</i> Deletion via Isochromosome 17q and Deletion 20q Mimicking a Myeloproliferative Neoplasm. [PDF]

J Med Cases
Gutierrez CLD, Quero-Taggaoa AKH.
europepmc   +1 more source

Probable sepsis‐associated encephalopathy as a component of multiple organ dysfunction syndrome in a cat with pyothorax

Australian Veterinary Journal, EarlyView.
A 2‐year‐old male neutered domestic shorthair cat with bacterial pyothorax was referred to a tertiary hospital for treatment of sepsis. He met criteria for multiple organ dysfunction syndrome and developed new‐onset neurological dysfunction subsequent to the development of sepsis.
CC Chan, CR Sharp, CJ Boyd
wiley   +1 more source

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy-Induced Neutropenia in Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial. [PDF]

Cancer Med
Wang J, Li H, Lin Q, Guo Y, Ma H, Xiang B, Yang C, Shen K, Zhang C, Yang K, Ma C, Zhai H, Wei J, Zuo Y, Zhou J, Niu T.   +15 more
europepmc   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Severe Immune Neutropenia Responsive to Ruxolitinib. [PDF]

EJHaem
Schwarzkopf R, Chen AAY, Elsharawi I, O'Reilly T, Chen LYC.   +4 more
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source